6 withdrawn. 6 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Withdrawn 6 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Bone Marrow Diseases: new trials by email Literature Review of Bone Marrow Diseases trials Research Report on Bone Marrow Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia Hetrombopag - Aplastic Anemia, Drug Effect | Phase 2 / Phase 3 | Withdrawn | Peking Union Medical College Hospital | 2021-10-01 | 2026-06-08 | |
| Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT Atorvastatin, Methotrexate, Tacrolimus - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 3 | Withdrawn | Loyola University | 2019-12-10 | 2021-04-27 | |
| Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) Decitabine, Arsenic Trioxide - Myelodysplastic Syndromes, P53 Mutation | Phase 3 | Withdrawn | Li Junmin | 2018-03-20 | 2023-08-16 | |
| Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL Dasatinib - Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Withdrawn | Bristol-Myers Squibb | 2006-12-01 | 2016-02-17 | |
| To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning Campath-1H /ATG - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 3 | Withdrawn | Hadassah Medical Organization | 203 | 2004-07-01 | 2011-04-08 |
| Bone Marrow Transplantation in Treating Patients With Leukemia anti-thymocyte globulin, cyclophosphamide, cyclosporine - Graft Versus Host Disease, Leukemia | Phase 3 | Withdrawn | Masonic Cancer Center, University of Minnesota | 1996-04-01 | 2020-01-03 |
Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Graft vs Host Disease (2) · Anemia, Aplastic (1) · Bronchiolitis Obliterans Syndrome (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma (1)
Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Leukemia, Myeloid (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia (3) · Leukemia, Lymphoid (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Chronic Disease (2) · Disease Attributes (2) · Myeloproliferative Disorders (2)
Methotrexate (2) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Arsenic (1) · Arsenic Trioxide (1) · Atorvastatin (1) · Cyclophosphamide (1) · Cyclosporine (1) · Dasatinib (1) · Decitabine (1) · Methylprednisolone (1) · Radiotherapy (1) · Tacrolimus (1) · hetrombopag (1)
Bristol-Myers Squibb (1) · Hadassah Medical Organization (1) · Li Junmin (1) · Loyola University (1) · Masonic Cancer Center, University of Minnesota (1) · Peking Union Medical College Hospital (1)
China (2) · United States (2) · Hungary (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Russia (1) · United Kingdom (1)
Bing Han, Master (1) · John E. Wagner, MD (1) · Lu Min (1) · Patrick Stiff, MD (1) · Shimon Slavin, MD (1) · Zhang Sujiang (1)